ArticlePloS one2009
Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 60 citations in OpenAlex.
- Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool.Frontiers in molecular biosciences · 2024Review
- Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer.British journal of cancer · 2023Article
- Targeting purine metabolism in ovarian cancer.Journal of ovarian research · 2022Review
- Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer.Cancer discovery · 2022Article
- Secretome Analysis of Inductive Signals for BM-MSC Transdifferentiation into Salivary Gland Progenitors.International journal of molecular sciences · 2020Article
- Estrogen enhances the proliferation and migration of ovarian cancer cells by activating transient receptor potential channel C3.Journal of ovarian research · 2020Article
- Review
- Diverse Effects of Lysophosphatidic Acid Receptors on Ovarian Cancer Signaling Pathways.Journal of oncology · 2019Article
- Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.Virchows Archiv : an international journal of pathology · 2018Article
- Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities.Cancer medicine · 2018Review
- Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p.Cancer letters · 2018Article
- Role of tumor microenvironment in ovarian cancer pathobiology.Oncotarget · 2018Review
- Dynamic relocalization of NHERF1 mediates chemotactic migration of ovarian cancer cells toward lysophosphatidic acid stimulation.Experimental & molecular medicine · 2017Article
- Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT.Oncotarget · 2016Article
- Article
- Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?Frontiers in oncology · 2014Review
- The gep proto-oncogene Gα12 mediates LPA-stimulated activation of CREB in ovarian cancer cells.Cellular signalling · 2014Article
- FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3.Endocrine-related cancer · 2013Article
- Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.Nature reviews. Cancer · 2013Article
- Orally administered phosphatidic acids and lysophosphatidic acids ameliorate aspirin-induced stomach mucosal injury in mice.Digestive diseases and sciences · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundLysophosphatidic acid (LPA) governs a number of physiologic and pathophysiological processes. Malignant ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian cancer cells, implicating LPA in the initiation and progression of ovarian cancer. However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian cancer. METHODOLOGY AND PRINCIPAL
findingsIn this study, gene expression profiling was used to examine LPA-mediated transcription by exogenously adding LPA to human epithelial ovarian cancer cells for 24 h to mimic long-term stimulation in the tumor microenvironment. The resultant transcriptional profile comprised a 39-gene signature that closely correlated to serous epithelial ovarian carcinoma. Hierarchical clustering of ovarian cancer patient specimens demonstrated that the signature is associated with worsened prognosis. Patients with LPA-signature-positive ovarian tumors have reduced disease-specific and progression-free survival times. They have a higher frequency of stage IIIc serous carcinoma and a greater proportion is deceased. Among the 39-gene signature, a group of seven genes associated with cell adhesion recapitulated the results. Out of those seven, claudin-1, an adhesion molecule and phenotypic epithelial marker, is the only independent biomarker of serous epithelial ovarian carcinoma. Knockdown of claudin-1 expression in ovarian cancer cells reduces LPA-mediated cellular adhesion, enhances suspended cells and reduces LPA-mediated migration.
conclusionsThe data suggest that transcriptional events mediated by LPA in the tumor microenvironment influence tumor progression through modulation of cell adhesion molecules like claudin-1 and, for the first time, report an LPA-mediated expression signature in ovarian cancer that predicts a worse prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.